NAS:IOVA (USA) Also trade in: Germany UK

Iovance Biotherapeutics Inc

$ 21.75 0.42 (1.97%)
Volume: 1,404,342 Avg Vol (1m): 1,897,231
Market Cap $: 2.68 Bil Enterprise Value $: 2.24 Bil
P/E (TTM): 0.00 P/B: 6.17
Earnings Power Value 3.43
Net Current Asset Value 3.39
Tangible Book 3.52
Projected FCF -0.77
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
85.53% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
IOVA: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 10000, Max: 10000
Current: 10000
0
10000
Interest Coverage No Debt
Interest Coverage ranked higher than
81.80% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
IOVA: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 59.17
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 13.53%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -38.99
ROE ranked lower than
55.41% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
IOVA: -38.99
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -1076.98, Med: -58.94, Max: -37.16
Current: -38.99
-1076.98
-37.16
ROA % -37.12
ROA ranked lower than
62.27% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
IOVA: -37.12
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -2532.68, Med: -128.13, Max: -36.26
Current: -37.12
-2532.68
-36.26
ROC (Joel Greenblatt) % -5129.43
ROC (Joel Greenblatt) ranked lower than
76.45% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
IOVA: -5129.43
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -146735.71, Med: -3701.31, Max: -1543.72
Current: -5129.43
-146735.71
-1543.72
3-Year Total EBITDA Growth Rate -68.00
3-Year EBITDA Growth Rate ranked lower than
84.54% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
IOVA: -29.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -737.9, Med: -27.6, Max: 74
Current: -29.3
-737.9
74
3-Year EPS w/o NRI Growth Rate -27.00
3-Year EPS w/o NRI Growth Rate ranked lower than
88.47% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
IOVA: -27
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» IOVA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IOVA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325411    SIC : 2834
Compare SZSE:002030 NAS:ALEC NAS:INVA NAS:CORT XKRX:006280 NAS:SGMO NYSE:CBM NAS:RUBY NAS:TBPH SHSE:600645 SHSE:603718 ROCO:4147 XKRX:095700 NAS:EDIT NAS:AIMT NYSE:MYOV NAS:ORTX NAS:APLS SZSE:002275 NAS:PBYI
Traded in other countries 2LB.Germany 0JDK.UK
Address 999 Skyway Road, Suite 150, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc operates in the healthcare sector based in the United States. It is a pharmaceutical manufacturer attending to serious diseases such as cancer. The Company's lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The TIL therapy involves growing a patient's special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient.

Ratios

Current vs industry vs history
PB Ratio 6.17
PB Ratio ranked lower than
54.78% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
IOVA: 6.17
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 9.25
Current: 6.17
0
9.25
EV-to-EBIT -15.87
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
IOVA: -15.87
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -18.71, Med: 0, Max: 0
Current: -15.87
-18.71
0
EV-to-EBITDA -15.98
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
IOVA: -15.98
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -18.94, Med: 0, Max: 0
Current: -15.98
-18.94
0
Current Ratio 20.09
Current Ratio ranked higher than
90.88% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
IOVA: 20.09
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.04, Med: 15.43, Max: 63.79
Current: 20.09
0.04
63.79
Quick Ratio 20.09
Quick Ratio ranked higher than
90.97% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
IOVA: 20.09
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.04, Med: 15.43, Max: 63.79
Current: 20.09
0.04
63.79

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -26.10
3-Year Share Buyback Rate ranked lower than
73.63% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
IOVA: -26.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -289.8, Med: -37.65, Max: 13.7
Current: -26.1
-289.8
13.7

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.17
Price-to-Tangible-Book ranked higher than
53.24% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
IOVA: 6.17
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.27, Med: 4.13, Max: 5000
Current: 6.17
2.27
5000
Earnings Yield (Joel Greenblatt) % -6.31
Earnings Yield (Greenblatt) ranked lower than
54.02% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
IOVA: -6.31
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1683.62, Med: 0, Max: 0
Current: -6.31
-1683.62
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N